Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

458.12 -7.22 (-1.55%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
News headline image
Alnylam's Concedes Its Patent Infringement Case Against Moderna's COVID-19 Vaccine ↗
Alnylam Pharmaceuticals has conceded that Moderna's products do not infringe on its patents, as a court ruling determined. Both companies have agreed to dismiss the case without prejudice for possible... 
Via Benzinga
Topics Intellectual Property
News headline image
If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,300 Today ↗
 
Via Benzinga
News headline image
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Looking Into Alnylam Pharmaceuticals's Recent Short Interest ↗
 
Via Benzinga
News headline image
Market Whales and Their Recent Bets on ALNY Options ↗
 
Via Benzinga
News headline image
$100 Invested In This Stock 5 Years Ago Would Be Worth $300 Today ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About Alnylam Pharmaceuticals? ↗
 
Via Benzinga
News headline image
Alnylam to Webcast TTR Investor Day
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure? ↗
Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares. 
Via Investor's Business Daily
News headline image
Alnylam Stock Soars 65%: Find Out What’s Behind the Gains
Alnylam Pharmaceutical is on the move. In early to mid-2025, the FDA is expected to approve expanded use of a key drug. 
Via MarketBeat
News headline image
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 10 Years ↗
 
Via Benzinga
News headline image
$100 Invested In This Stock 20 Years Ago Would Be Worth $4,100 Today ↗
 
Via Benzinga
News headline image
Peering Into Alnylam Pharmaceuticals's Recent Short Interest ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Alnylam Pharmaceuticals Stock Falls After Detailed Vutrisiran Data For A Condition With Stiff Heart Muscles ↗
Alnylam Pharmaceuticals shares drop as detailed results from the HELIOS-B Phase 3 study of vutrisiran for ATTR-CM reveal mixed outcomes. Reductions in mortality and cardiovascular events were presented... 
Via Benzinga
News headline image
Alnylam Plummets, Reversing 50% Gain This Year, As Pfizer Rival Lags Expectations ↗
The company is hoping to rival Pfizer's approved treatment for cardiomyopathy. 
Via Investor's Business Daily
News headline image
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 10 Years ↗
 
Via Benzinga
News headline image
The 3 Best Gene Editing Stocks to Buy in August 2024 ↗
These are the best gene-editing stocks to buy as the biotechs pursue precision therapies to cure rare diseases. 
Via InvestorPlace
News headline image
Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82 ↗
On Tuesday, Avadel Pharmaceuticals stock received a positive adjustment to its Relative Strength (RS) Rating, from 76 to 82. 
Via Investor's Business Daily
News headline image
DoorDash And Exact Sciences Are Among Top 10 Large Cap Gainers Last Week (July 28-Aug 3): Are The Others In Your Portfolio? ↗
Top 10 stocks with highest gains last week, including Exact Sciences, Alnylam Pharmaceuticals, Resmed, Coca-Cola Consolidated, DexCom, Sprouts Farmers Market, UL Solutions, Labcorp Holdings, C.H.... 
Via Benzinga
News headline image
Air Products Posts Upbeat Earnings, Joins Meta, Exact Sciences, Shake Shack, Clearwater Analytics And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst ↗
Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety... 
Via Benzinga
News headline image
Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Stock Is a Blockbuster Biopharma In the Making ↗
Alnylam stock could significantly pad its initial gains if vutrisiran gains expedited approval to hit the market. 
Via InvestorPlace
News headline image
35% Surge Just the Beginning? Alnylam’s Stock Poised for Massive Gains on Heart Drug Success. ↗
Alnylam Pharmaceuticals stock recently popped and could continue to move higher on Alnylam Pharmaceuticals' cardiovascular drug announcement. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.